GU Cancers 2020 | Optimizing immunotherapy duration
Thanks for your feedback, this will help us improve our content for you!
Hans Hammers, MD, PhD, The University of Texas Southwestern, Dallas, TX, discusses the importance of individualized approaches to determine the best duration of immunotherapy treatment. Specifically, he focuses on the need to optimize patient outcomes and reducing unnecessary costs. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up